Heart failure: Erythropoietin in treatment of anemia [18]

dc.authorscopusid55980615600
dc.contributor.authorBüyüklü M.
dc.date.accessioned2024-06-12T10:28:57Z
dc.date.available2024-06-12T10:28:57Z
dc.date.issued2007
dc.description.abstract[No abstract available]en_US
dc.identifier.endpage343en_US
dc.identifier.issn1302-8723
dc.identifier.issue3en_US
dc.identifier.pmid17785241en_US
dc.identifier.scopus2-s2.0-34648817180en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage342en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17500
dc.identifier.volume7en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isotren_US
dc.relation.ispartofAnadolu Kardiyoloji Dergisien_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcetylsalicylic Acid; Dipeptidyl Carboxypeptidase Inhibitor; Hemoglobin; Novel Erythropoiesis Stimulating Protein; Recombinant Erythropoietin; Tumor Necrosis Factor Alpha; Erythropoietin; Anemia; Angiogenesis; Blood Transfusion; Cardiovascular Risk; Glomerulus Filtration Rate; Heart Failure; Hemoglobin Determination; Human; Letter; Plasma Volume; Thrombosis; Anemia; Female; Heart Failure; Hospitalization; Male; Pathology; Anemia; Erythropoietin; Female; Heart Failure; Humans; Male; Severity Of Illness Indexen_US
dc.titleHeart failure: Erythropoietin in treatment of anemia [18]en_US
dc.title.alternativeKalp yetersizligi: Anemi tedavisinde eritropoetinen_US
dc.typeLetteren_US

Dosyalar